clinical trial manager new york

Stocks2Watch to Host Investor Luncheon with Special Guest, Bruce Campbell from StoneCastle Investment Management, Tuesday November 30th

Stocks2Watch Investor Series today announced their agenda is set for the Investor Luncheon with Special Guest, Bruce Campbell from StoneCastle Investment Management, Tuesday November 30. Individual investors, institutional investors, advisors, and analysts are invited to register now to attend the Luncheon.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

Gain market insight, find investment opportunities, and consider investing in StoneCastle's various funds… all safely in the comfort of your office/home using our latest technology. Confirmed Investor & Finance Professionals will receive a gift certificate to order in lunch on Tuesday, November 30.

LUNCHEON AGENDA: (Eastern Time)

12:00PM: Market Outlook - Bruce Campbell, Portfolio Manager at StoneCastle
12:20PM: Quipt Home Medical (Healthcare) TSX.V: QIPT
12:40PM: PlantFuel Life (Life Science) CSE: FUEL
1:00PM: Levitee Labs (Healthcare) CSE: LVT
1:20PM: New "Stocks2Watch" Picks by Bruce Campbell, Portfolio Manager at StoneCastle

Registration Open to Investors and Finance Professionals >>> This event is suitable for private investors, brokers, fund managers, financial institutions, funds, buy & sell side analysts, influencers, newsletter writers and journalists. The event is not suitable for people pursuing commercial opportunities.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

ABOUT STOCKS2WATCH:

Stocks2Watch hosts online and in-person interactive events for publicly-traded companies to meet and present directly with investors. To learn more about Stocks2Watch and view a complete list of events, please visit www.stocks2watch.ca

NEXT LUNCHEON: Scheduled for Thursday January 20th

CONTACT:

Neil Lock,
info@stocks2watch.ca
604-410-4888

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104215

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Levitee Labs

Levitee Labs

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
Sunlit mushrooms growing on forest floor, backlit to show vibrant gills and earthy texture.

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks. While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and... Keep Reading...

Latest Press Releases

Related News